Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant.

Jill N Modi Sarah K Cimino

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Co-administration of fosaprepitant and ifosfamide in sarcoma appears to be safe. Hypoalbuminemia was a notable risk factor confirmed in this study. Further research is needed to delineate IIE risk factors.

Keyphrases

risk factors
high glucose
diabetic rats
drug induced
stress induced